|
Patients [n], (%)
|
84
|
50 (60)
|
34 (40)
|
-
|
|
Age, median [years] (IQR)
|
69.0 (62.3–76.0)
|
68.0 (61.0–75.5)
|
70.5 (66.5–76.0)
|
0.304
|
|
Lnn. Metastases [n] (%)
|
45 (53.6)
|
27 (54.0)
|
18 (52.9)
|
0.924
|
|
Visceral Metastases [n] (%)
|
17 (20.2)
|
14 (28.0)
|
3 (8.8)
|
0.032
|
|
Pre CTX [n] (%)
|
39 (46.4)
|
24 (48.0)
|
15 (44.1)
|
0.726
|
|
Post CTX [n] (%)
|
45 (53.6)
|
26 (52.0)
|
19 (55.9)
|
0.726
|
|
Patients died [n] (%)
|
53 (63.1)
|
39 (78.0)
|
14 (41.2)
|
-
|
|
Antiresorptive therapy [n] (%)
|
56 (66.7)
|
32 (64.0)
|
24 (70.6)
|
0.530
|
|
Zoledronic acid [n] (%)
|
42 (50.0)
|
24 (48.0)
|
18 (52.9)
|
0.821
|
|
Denosumab [n] (%)
|
14 (16.7)
|
8 (16.0)
|
6 (17.6)
|
|
Best clinical outcome [n] (%)
| | | | |
|
CR
|
1 (1.2)
|
0 (0)
|
1 (2.9)
|
<0.001
|
|
PR
|
51 (60.7)
|
22 (44.0)
|
29 (85.3)
|
|
SD
|
20 (23.8)
|
16 (32.0)
|
4 (11.8)
|
|
PD
|
12 (14.3)
|
12 (24.0)
|
0 (0)
|
|
ECOG (all) [n] (%)
| | | | |
|
0
|
12 (14.3)
|
7 (14.0)
|
5 (14.7)
|
0.351
|
|
1
|
53 (63.1)
|
29 (58.0)
|
24 (70.6)
| |
|
2
|
29 (22.6)
|
14 (28.0)
|
5 (14.7)
| |
|
GS ≥ 8 [n] (%)a
|
45 (60.8)
|
29 (67.4)
|
16 (51.6)
|
0.169
|
|
PSA red. ≥ 50 % [n] (%)
|
47 (56.0)
|
19 (38.0)
|
28 (82.4)
|
<0.001
|
|
PSA red. ≥ 90 % [n] (%)
|
22 (26.2)
|
6 (12.0)
|
16 (47.1)
|
<0.001
|
|
Median PSA Baseline [ng/ml] (IQR)
|
174 (55–500)
|
105 (47–457)
|
151 (54–477)
|
0.824
|
|
Median LDH Baseline [U/l] (IQR)
|
287 (223–422)
|
290 (228–565)
|
252 (218–327)
|
0.125
|
|
Median ALP Baseline [U/l] (IQR)
|
155 (102–355)
|
171 (96–381)
|
154 (114–273)
|
0.895
|
|
ALP rising at 12 w AA [n] (%)
|
27 (33.3)
|
27 (57.4)
|
0 (0)
|
-
|
|
LDH BL > UNL [n] (%)
|
58 (71.6)
|
37 (77.1)
|
21 (63.6)
|
0.187
|
|
LDH normalization [n] (%)
|
23 (39.0)
|
10 (27.0)
|
13 (59.1)
|
0.015
|
